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BACKGROUND 
The introduction of biologic therapies revolutionised treatment of psoriasis and psoriatic arthritis (PsA)
 Recommendations for treatment of psoriasis ( Figure 1 and Table 1 ) and
PsA (Table 2) with biologics revised over time. 

The aim of the registry is to explore the long-term safety of biologic agents compared to conventional systemic agents.
OBJECTIVES
To describe patterns of index biologic registrations for biologic-naïve psoriasis patients in BADBIR by:
(i) country (England; Northern Ireland (NI); ROI; Scotland; Wales);
(ii) comorbid PsA.
METHODS

Figure 2: BADBIR study design
Inclusion: registration to biologic cohort before 01/01/2016 (n=7495);
Exclusion: prior biologic exposure (n=1345);
Outcomes: country of registration; prevalent PsA.
RESULTS
 6140 biologic-naïve patients (82% biologic cohort); median age 45 years, inter-quartile range 36-54 years; 60% male.
 Registrations by country: England (n=4697; 76%); NI (n=299; 5%); ROI (n=289; 5%); Scotland (n=525; 9%); Wales (n=330; 5%).
 Humira (57%) was the most common index biologic (23% Enbrel; 18% Stelara; 2% Remicade). 
